Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 4/20 | 0.46 |
| ▸ | RARB | P10826 | 3/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7755968 | 0.93 | PTPN11 (0.44) | PTPN11RARBNFKB1NFKB2RELA | |
| SCHEMBL6676195 | 0.91 | PTPN11 (0.37) | PTPN11RARBNFKB1NFKB2RELA | |
| SCHEMBL6681424 | 0.88 | PTPN11 (0.53) | PTPN11RARBLMNATP53TSHR | |
| SCHEMBL6681432 | 0.84 | PTPN11 (0.46) | PTPN11RARBNPC1PDK2 | |
| SCHEMBL5546811 | 0.84 | PTPN11 (0.46) | PTPN11RARBNPC1PDK2 | |
| SCHEMBL19484788 | 0.83 | MAPT (0.43) | PTPN11NFKB1NFKB2RELANPC1 | |
| SCHEMBL7760968 | 0.77 | PTPN11 (0.44) | PTPN11RARBNPC1PDK2 | |
| SCHEMBL5546824 | 0.75 | CNR2 (0.54) | PTPN11 | |
| SCHEMBL5546820 | 0.74 | CYP3A4 (0.47) | PTPN11RARBNPC1SMN1; SMN2 | |
| SCHEMBL22017469 | 0.73 | POLB (0.41) | PTPN11NFKB1NFKB2RELANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1089984-B1 | NON-YELLOWING PARA-TERTIARY-ALKYL PHENYL SUBSTITUTED TRIAZINE AND PYRIMIDINE ULTRAVIOLET LIGHT ABSORBERS | CYTEC TECH CORP (US) | 2004-10-27 | — | — | EP | disclosed |
| US-6509399-B2 | Radiation resistance; absorber | CYTEC TECHNOLOGY CORP | 2003-01-21 | — | — | US | disclosed |
| US-20020013462-A1 | Non-yellowing part-tertiary-alkyl phenyl substituted triazine and pyrimidine ultraviolet light absorbers | CYTEC INDUSTRIES CORP. | 2002-01-31 | — | — | US | disclosed |
| US-20010031867-A1 | Non-yellowing para-tertiary-alkyl phenyl substituted triazineand pyrimidine ultraviolet light absorbers | CYTEC INDUSTRIES CORP. | 2001-10-18 | — | — | US | disclosed |
| US-6239276-B1 | STABILIZER | CYTEC TECHNOLOGY CORPORATION | 2001-05-29 | — | — | US | disclosed |
| EP-1089984-A1 | NON-YELLOWING PARA-TERTIARY-ALKYL PHENYL SUBSTITUTED TRIAZINE AND PYRIMIDINE ULTRAVIOLET LIGHT ABSORBERS | CYTEC TECHNOLOGY CORP. (US) | 2001-04-11 | — | — | EP | disclosed |
| WO-1999067226-A1 | NON-YELLOWING PARA-TERTIARY-ALKYL PHENYL SUBSTITUTED TRIAZINE AND PYRIMIDINE ULTRAVIOLET LIGHT ABSORBERS | CYTEC TECHNOLOGY CORP. (US) | 1999-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031867-A1 | Non-yellowing para-tertiary-alkyl phenyl substituted triazineand pyrimidine ultraviolet light absorbers | TERB1, RAD52, ERCC4 | PTPN11 333/4885RARB 437/4885NFKB1 2792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.